Correlation Between Alnylam Pharmaceuticals and Ultragenyx

Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Ultragenyx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Ultragenyx into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alnylam Pharmaceuticals and Ultragenyx, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Ultragenyx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Ultragenyx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Ultragenyx.

Diversification Opportunities for Alnylam Pharmaceuticals and Ultragenyx

0.55

Correlation Coefficient

Alnylam Pharmaceuticals  Ultragenyx

Very weak diversification

The 3 months correlation between Alnylam and Ultragenyx is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Ultragenyx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ultragenyx and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Ultragenyx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ultragenyx has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Ultragenyx go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals and Ultragenyx

Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to generate 1.11 times more return on investment than Ultragenyx. However, Alnylam Pharmaceuticals is 1.11 times more volatile than Ultragenyx. It trades about 0.01 of its potential returns per unit of risk. Ultragenyx is currently generating about -0.11 per unit of risk. If you would invest  25,378  in Alnylam Pharmaceuticals on August 31, 2024 and sell it today you would lose (4.00) from holding Alnylam Pharmaceuticals or give up 0.02% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Alnylam Pharmaceuticals  vs.  Ultragenyx

Alnylam Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Alnylam Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Ultragenyx

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Alnylam Pharmaceuticals and Ultragenyx

The main advantage of trading using opposite Alnylam Pharmaceuticals and Ultragenyx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Ultragenyx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ultragenyx will offset losses from the drop in Ultragenyx's long position.

The idea behind Alnylam Pharmaceuticals and Ultragenyx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.